Literature DB >> 8031546

Central obesity and hypertension. Relationship between fasting serum insulin, plasma renin activity, and diastolic blood pressure in young obese subjects.

G Licata1, R Scaglione, A Ganguzza, S Corrao, M Donatelli, G Parrinello, M A Dichiara, G Merlino, M G Cecala.   

Abstract

This study was designed to evaluate the role of fasting serum insulin and plasma renin activity in obesity-induced hypertension. In view of this, plasma catecholamines, fasting serum insulin (IRI), urinary sodium excretion (NaU), plasma renin activity (PRA), and plasma aldosterone (PA) levels were assessed in young (age less than 40 years) normotensive (n = 27) and hypertensive (n = 14) subjects with central obesity and in lean normotensives (n = 20). Central obesity was evaluated by waist-to-hip ratio (WHR) according to the indication of the Italian Consensus Conference of Obesity. PRA, PA, IRI, and plasma norepinephrine levels were significantly (P < .05) higher in both obese groups than in lean normotensives. PRA was significantly (P < .05) higher and NaU was significantly (P < .05) lower in obese hypertensives than in obese normotensives. Diastolic blood pressure correlated directly with WHR and PRA in normotensive and hypertensive obese subjects and with IRI but only in normotensive obese subjects. Multiple regression analysis indicated that diastolic blood pressure values increased with WHR (P < .05), IRI (P < .005), and PRA (P < .002), but not with body mass index, NaU, and norepinephrine levels. Our results indicated that increased PRA could play an important role in the development of hypertension in subjects with central obesity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8031546     DOI: 10.1093/ajh/7.4.314

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  15 in total

1.  Intra-abdominal fat and elevated urine albumin excretion in men with type 1 diabetes.

Authors:  Shalamar D Sibley; Ian H de Boer; Michael W Steffes; John D Brunzell
Journal:  Diabetes Care       Date:  2007-04-24       Impact factor: 19.112

2.  Aliskiren combined with losartan: Thor's hammer or Sigurd's sword?

Authors:  Thomas R Lux; Heinrich Taegtmeyer
Journal:  Curr Hypertens Rep       Date:  2008-12       Impact factor: 5.369

Review 3.  Fat tissue metabolism and adrenal steroid secretion.

Authors:  Valéria Lamounier-Zepter; Monika Ehrhart-Bornstein
Journal:  Curr Hypertens Rep       Date:  2006-04       Impact factor: 5.369

4.  Mineralocorticoid receptor antagonism prevents obesity-induced cerebral artery remodeling and reduces white matter injury in rats.

Authors:  Paulo W Pires; Jonathon L McClain; Sebastian F Hayoz; Anne M Dorrance
Journal:  Microcirculation       Date:  2018-06-07       Impact factor: 2.628

5.  The effect of angiotensin-converting enzyme inhibition using captopril on energy balance and glucose homeostasis.

Authors:  Annette D de Kloet; Eric G Krause; Dong-Hoon Kim; Randall R Sakai; Randy J Seeley; Stephen C Woods
Journal:  Endocrinology       Date:  2009-06-04       Impact factor: 4.736

Review 6.  Nondiabetic consequences of obesity on kidney.

Authors:  Tarak Srivastava
Journal:  Pediatr Nephrol       Date:  2006-02-21       Impact factor: 3.714

Review 7.  Cardiometabolic syndrome: pathophysiology and treatment.

Authors:  Jonathan P Castro; Fadi A El-Atat; Samy I McFarlane; Ashish Aneja; James R Sowers
Journal:  Curr Hypertens Rep       Date:  2003-10       Impact factor: 5.369

8.  Body mass index predicts aldosterone production in normotensive adults on a high-salt diet.

Authors:  Rhonda Bentley-Lewis; Gail K Adler; Todd Perlstein; Ellen W Seely; Paul N Hopkins; Gordon H Williams; Rajesh Garg
Journal:  J Clin Endocrinol Metab       Date:  2007-08-28       Impact factor: 5.958

9.  Adipocyte deficiency of angiotensinogen prevents obesity-induced hypertension in male mice.

Authors:  Frederique Yiannikouris; Manisha Gupte; Kelly Putnam; Sean Thatcher; Richard Charnigo; Debra L Rateri; Alan Daugherty; Lisa A Cassis
Journal:  Hypertension       Date:  2012-10-29       Impact factor: 10.190

10.  Human adipocytes secrete mineralocorticoid-releasing factors.

Authors:  M Ehrhart-Bornstein; V Lamounier-Zepter; A Schraven; J Langenbach; H S Willenberg; A Barthel; H Hauner; S M McCann; W A Scherbaum; S R Bornstein
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.